IL-17及血浆水平与HCV感染的关系

2013-07-25 佚名 中华肝病网

  为探讨白细胞介素17(IL-17)单核苷酸多态性(SNPs)及血浆水平与慢性HCV(丙型肝炎病毒)感染的关系。河北医科大学第三医院中西医结合肝病科研究人员选择慢性丙型肝炎(CHC)患者228例,健康体检者81例。TaqMan探针法检测IL-17 rs 8193036及rs 2275913位点基因多态性,酶联免疫吸附法检测血浆IL-17水平,分析CHC患者IL-17等位基

  为探讨白细胞介素17(IL-17)单核苷酸多态性(SNPs)及血浆水平与慢性HCV(丙型肝炎病毒)感染的关系。河北医科大学第三医院中西医结合肝病科研究人员选择慢性丙型肝炎(CHC)患者228例,健康体检者81例。TaqMan探针法检测IL-17 rs 8193036及rs 2275913位点基因多态性,酶联免疫吸附法检测血浆IL-17水平,分析CHC患者IL-17等位基因、基因型及血浆水平与健康人群的差异。

  结果显示,CHC患者组与健康对照组IL-17 rs8193036位点C、T等位基因及rs2275913位点A、G等位基因分布比较,P值均> 0.05,差异均无统计学意义。CHC患者组与健康对照组的IL-17 rs8193036位点基因型CC(46.49%对比41.98%)、CT(45.61%对比44.44%)、TT(7.89%对比13.58%)分布比较,P值均> 0.05,差异均无统计学意义; rs 2275913位点基因型AA(16.23%对比13.58%)、AG(48.25%对比50.62%)、GG(35.53%对比35.80%)分布比较,P值均> 0.05,差异均无统计学意义。HCV基因1型与2型感染CHC患者IL-17 rs8193036及rs2275913位点等位基因及基因型分布比较,P值均> 0.05,差异均无统计学意义。CHC患者组血浆IL-17水平为(97.67 ± 39.68)pg/ml显著高于健康对照组的(71.60 ± 19.78)pg/ml,两组比较t = 2.414,P = 0.033,差异有统计学意义。

  该研究结论提示:IL-17高水平表达在HCV感染及慢性化中发挥重要作用,而IL-17 rs 8193036及rs 2275913位点SNPs可能与HCV易感性及持续感染无明确关系。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1257568, encodeId=67c3125e56805, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374396, encodeId=5c4713e43962d, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508159, encodeId=0f5a150815955, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618949, encodeId=7b6a1618949ea, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2013-07-26 ymljack
  2. [GetPortalCommentsPageByObjectIdResponse(id=1257568, encodeId=67c3125e56805, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374396, encodeId=5c4713e43962d, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508159, encodeId=0f5a150815955, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618949, encodeId=7b6a1618949ea, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1257568, encodeId=67c3125e56805, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374396, encodeId=5c4713e43962d, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508159, encodeId=0f5a150815955, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618949, encodeId=7b6a1618949ea, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2013-07-26 jjjiang0202
  4. [GetPortalCommentsPageByObjectIdResponse(id=1257568, encodeId=67c3125e56805, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374396, encodeId=5c4713e43962d, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508159, encodeId=0f5a150815955, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618949, encodeId=7b6a1618949ea, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Fri Jul 26 22:49:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]

相关资讯

JAMA:持续病毒学应答或增慢性丙肝患者存活率

  据发表在12月26日出版的《美国医学会杂志》上的一项研究披露,在患有慢性丙型肝炎病毒感染及晚期肝纤维化(生长出过多的纤维结缔组织)的患者中,与那些没有持续病毒学应答(SVR)的患者相比,那些患者对以干扰素为基础的治疗作出的持续病毒学应答(SVR)与较低的全因死亡率有关。   根据文章的背景资料:“慢性丙型肝炎病毒(HCV)感染是肝硬化、肝细胞性肝癌(HCC)及终末期肝病的一个主要原因。HCV